(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 January 2015 (29.01.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/013168 A1

(51) International Patent Classification:
C07K 14/47 (2006.01) *A61P 9/04* (2006.01)
A61K 38/17 (2006.01)

(21) International Application Number:
PCT/US2014/047377

(22) International Filing Date:
21 July 2014 (21.07.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/858,263 25 July 2013 (25.07.2013) US
62/015,854 23 June 2014 (23.06.2014) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Novartis Ag, Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(71) Applicants *(for US only)*: **BRUCE, Alexandra Marshall** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **GROSCHE, Philipp** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **GUIMARAES, Carla** [PT/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **KANTER, Aaron** [US/US]; 20 Brastow Ave., Somerville, Massachusetts 02143 (US). **LOU, Changgang** [CN/US]; 3681 Fawn Cove Lane, Apt. 1, Portage, Michigan 49024 (US). **USERA, Aimee Richardson** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **YASOSHIMA, Kayo** [JP/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **YUAN, Jun** [US/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US). **ZECRI, Frederic** [FR/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **ZHAO, Hongjuan** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

(74) Common Representative: **NOVARTIS AG**; NOVARTIS AG, Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

[Continued on next page]

(54) Title: CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE

X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13

(I)

(57) Abstract: The invention provides a cyclic polypeptide of Formula I': I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

WO 2015/013168 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*